SCHEMBL23364602

SCHEMBL23364602

CC(C)c1ccccc1-c1nc(N)sc1I

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 2/20 0.40
▸ NPY5R Q15761 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ DAPK3 O43293 1/20 0.40
▸ LTK P29376 1/20 0.40
▸ MAPK8 P45983 1/20 0.40
▸ CSNK1A1 P48729 1/20 0.40
▸ CDK8 P49336 1/20 0.40
▸ LIMK1 P53667 1/20 0.40
▸ CDK5 Q00535 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ DYRK1B Q9Y463 1/20 0.40
▸ ADORA1 P30542 2/20 0.39
▸ DHFR P00374 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932826 1.00 FBP1 (0.40) FBP1NPY5RCHEK1DAPK3LTK
SCHEMBL31627031 0.76 MYC (0.56) FBP1NPY5RCHEK1DAPK3LTK
SCHEMBL29932816 0.72 MPL (0.55) NPY5RCHEK1DAPK3LTKMAPK8
SCHEMBL23364821 0.72 MPL (0.55) NPY5RCHEK1DAPK3LTKMAPK8
SCHEMBL2175865 0.71 ALDH1A1 (0.63) FBP1ALDH1A1KDM4ELMNAGAA
SCHEMBL29932854 0.69 HSD17B10 (0.57) ALDH1A1KDM4ELMNAMAPTCYP1A2
SCHEMBL23364703 0.69 HSD17B10 (0.57) ALDH1A1KDM4ELMNAMAPTCYP1A2
SCHEMBL11324864 0.69 ALDH1A1 (0.59) ALDH1A1KDM4ELMNAGAA
SCHEMBL23364566 0.68 ALDH1A1 (0.49) FBP1NPY5RADORA1ALDH1A1KDM4E
SCHEMBL167078 0.66 GABRA1 (0.55) DHFRALDH1A1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION 2024-01-04 — — US disclosed
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 — — EP disclosed
CN-115003659-A 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity 健赞公司 2022-09-02 — — CN disclosed
WO-2021097057-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION (US) 2021-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY CFTR, PKD2, PKD1 FBP1 1436/4885NPY5R 4004/4885CHEK1 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback